Extend Your Research Possibilities

Extend Your Research Possibilities

• Optimized for PCR Targets From 20kb to 50 kb in Length
• Amplifies Long complex Genomic Targets with Ease
• Higher Fidelity than Other Taq-Based DNA Polymerase Blends

Extremely long PCR templates present unique challenges, which include the length of the target, complex secondary structures and lengthy extension times.

EXL™ DNA polymerase^*,‡ is a unique DNA polymerase formulation that excels at amplifying extra long targets with robust yield, specificity and higher fidelity than Taq DNA polymerase or Taq-based blends. It successfully amplifies genomic targets up to 37 kb and lambda targets up to

Specialized Formulation for Unique Challenges

The difficulty in amplifying extremely long genomic targets is not just length alone. Secondary structures and repetitive sequences are common within long DNA templates and can interfere with polymerization. Moreover, exposing the DNA template and PCR reagents to lengthy extension times required for amplifying long targets can limit PCR efficiency. EXL DNA polymerase provides optimum performance in these extreme situations. It successfully amplifies genomic targets up to 37 kb and lambda targets up to approximately 50 kb. EXL DNA polymerase comes with an optimized PCR buffer for extreme target lengths, a stabilizing solution and DMSO— which together enable robust amplification of extremely long targets (Figure 1).

Greater Accuracy Means Greater Success

EXL DNA polymerase exhibits higher fidelity than Taq and other Taq-based DNA polymerase blends. EXL is based on Pfu DNA polymerase, the highest fidelity enzyme available, blended with Taq DNA polymerase and other novel components to boost performance with extremely long targets. The lower error rate (mutations per bp) of EXL DNA polymerase ensures that fewer mistakes will be made during amplification of long targets compared to PCRs carried out with Taq-based enzyme formulations. EXL DNA polymerase’s superiorperformance in amplifying extra long targets leads to greater success in downstream applications.

Contributing Scientists
Stratagene: Holly Hogrefe and Mike Borns

* U.S. Patent Nos. 6,183,997 and 5,948,663 and 5,866,395 and 5,556,772 and 5,545,552 and patents pending.